{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:36:25Z","timestamp":1792287385452,"version":"4.4.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12282-026-01856-1","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T08:33:55Z","timestamp":1775550835000},"page":"569-581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Niraparib in breast cancer: evidence-based perspective on translational progress"],"prefix":"10.1007","volume":"33","author":[{"given":"Kushant","family":"Chauhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushboo","family":"Bisht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2715-7402","authenticated-orcid":false,"given":"Madhu","family":"Bala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"3","key":"1856_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1856_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60010168","volume":"60","author":"L Lopez-Gonzalez","year":"2024","unstructured":"Lopez-Gonzalez L, Sanchez Cendra A, Sanchez Cendra C, et al. Exploring biomarkers in breast cancer: hallmarks of diagnosis, treatment, and follow-up in clinical practice. Medicina. 2024;60:168.","journal-title":"Medicina"},{"issue":"10","key":"1856_CR3","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1158\/1055-9965.EPI-12-0474","volume":"21","author":"R Haque","year":"2012","unstructured":"Haque R, Ahmed SA, Inzhakova G, et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1848\u201355.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1856_CR4","doi-asserted-by":"publisher","first-page":"e1321654","DOI":"10.3389\/fonc.2024.1321654","volume":"14","author":"F Carlino","year":"2024","unstructured":"Carlino F, Solinas C, Orditura M, et al. Editorial: Heterogeneity in breast cancer: clinical and therapeutic implications. Front Oncol. 2024;14:e1321654.","journal-title":"Front Oncol"},{"issue":"14","key":"1856_CR5","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1038\/s41388-020-1191-x","volume":"39","author":"H Wang","year":"2020","unstructured":"Wang H, Zhang S, Song L, et al. Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells. Oncogene. 2020;39(14):2905\u201320.","journal-title":"Oncogene"},{"key":"1856_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18:610\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"1856_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s43018-022-00400-2","volume":"3","author":"LM Spring","year":"2022","unstructured":"Spring LM, Han H, Liu MC, et al. Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nat Cancer. 2022;3(8):927\u201331.","journal-title":"Nat Cancer"},{"issue":"2","key":"1856_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/1541-7786.MCR-18-0138","volume":"17","author":"TA Hopkins","year":"2019","unstructured":"Hopkins TA, Ainsworth WB, Ellis PA, et al. PARP1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow. Mol Cancer Res. 2019;17(2):409\u201319.","journal-title":"Mol Cancer Res"},{"key":"1856_CR9","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.2147\/OTT.S139336","volume":"10","author":"A Ohmoto","year":"2017","unstructured":"Ohmoto A, Yachida S. Current status of poly (ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther. 2017;10:5195\u2013208.","journal-title":"Onco Targets Ther"},{"key":"1856_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","volume":"61","author":"MAC Bruin","year":"2022","unstructured":"Bruin MAC, Sonke GS, Beijnen JH, et al. Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology. Clin Pharmacokinet. 2022;61:1649\u201375.","journal-title":"Clin Pharmacokinet"},{"issue":"20","key":"1856_CR11","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1158\/1078-0432.CCR-21-0310","volume":"27","author":"NC Turner","year":"2021","unstructured":"Turner NC, Balma\u00f1a J, Poncet C, et al. Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG\/ BIG5\u201313\/TESARO PR-30\u201350\u201310-C BRAVO study. Clin Cancer Res. 2021;27(20):5482\u201391.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1856_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/17512433.2018.1513321","volume":"11","author":"D Le","year":"2018","unstructured":"Le D, Gelmon KA. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer. Expert Rev Clin Pharmacol. 2018;11(9):833\u20139.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"1856_CR13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1358\/dot.2019.55.7.3015642","volume":"55","author":"GG Eskiler","year":"2019","unstructured":"Eskiler GG. Talazoparib to treat BRCA-positive breast cancer. Drugs Today. 2019;55(7):459\u201367.","journal-title":"Drugs Today"},{"key":"1856_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.sbi.2018.11.002","volume":"53","author":"MF Langelier","year":"2018","unstructured":"Langelier MF, Eisemann T, Riccio AA, et al. PARP family enzymes: regulation and catalysis of the poly (ADP-ribose) posttranslational modification. Curr Opin Struct Biol. 2018;53:187\u201398.","journal-title":"Curr Opin Struct Biol"},{"key":"1856_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00018-019-03366-0","volume":"77","author":"E Travis","year":"2020","unstructured":"Travis E, John MP. Poly (ADP-ribose) polymerase enzymes and the maintenance of genome integrity. Cell Mol Life Sci. 2020;77:19\u201333.","journal-title":"Cell Mol Life Sci"},{"key":"1856_CR16","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1126\/science.1216338","volume":"336","author":"MF Langelier","year":"2012","unstructured":"Langelier MF, Planck JL, Roy S, et al. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science. 2012;336:728\u201332.","journal-title":"Science"},{"key":"1856_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105112","volume":"22","author":"L Van Beek","year":"2021","unstructured":"Van Beek L, McClay \u00c9, Patel S, et al. PARP power: a structural perspective on PARP1, PARP2, and PARP3 in DNA damage repair and nucleosome remodelling. Int J Mol Sci. 2021;22:e5112.","journal-title":"Int J Mol Sci"},{"key":"1856_CR18","doi-asserted-by":"publisher","first-page":"e114049","DOI":"10.1016\/j.ejmech.2021.114094","volume":"230","author":"X Hu","year":"2022","unstructured":"Hu X, Zhang J, Zhang Y, et al. Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities. Eur J Med Chem. 2022;230:e114049.","journal-title":"Eur J Med Chem"},{"issue":"9","key":"1856_CR19","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1093\/nar\/gkz120","volume":"47","author":"EE Alemasova","year":"2019","unstructured":"Alemasova EE, Lavrik OI. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins. Nucleic Acids Res. 2019;47(9):3811\u201327.","journal-title":"Nucleic Acids Res"},{"key":"1856_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.12.002","volume":"73","author":"E Franzese","year":"2019","unstructured":"Franzese E, Centonze S, Diana A, et al. PARP inhibitors in ovarian cancer. Cancer Treat Rev. 2019;73:1\u20139.","journal-title":"Cancer Treat Rev"},{"key":"1856_CR21","doi-asserted-by":"publisher","first-page":"e2773","DOI":"10.3390\/ijms26062773","volume":"24","author":"K De","year":"2025","unstructured":"De K, Jana M, Chowdhury B, et al. Role of PARP Inhibitors: A new hope for breast cancer therapy. Int J Mol Sci. 2025;24:e2773.","journal-title":"Int J Mol Sci"},{"key":"1856_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40246-022-00447-3","volume":"17","author":"J Kim","year":"2023","unstructured":"Kim J, Jeong K, Jun H, et al. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1\/2 mutations. Hum Genomics. 2023;17:1\u201310.","journal-title":"Hum Genomics"},{"key":"1856_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47080638","volume":"47","author":"B Shah","year":"2025","unstructured":"Shah B, Hussain M, Seth A. Homologous recombination deficiency in ovarian and breast cancers: biomarkers, diagnosis, and treatment. Curr Issues Mol Biol. 2025;47:e638.","journal-title":"Curr Issues Mol Biol"},{"key":"1856_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","volume":"16","author":"L Cortesi","year":"2021","unstructured":"Cortesi L, Rugo HS, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021;16:255\u201382.","journal-title":"Target Oncol"},{"key":"1856_CR25","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1186\/s12916-015-0425-1","volume":"13","author":"L Livraghi","year":"2015","unstructured":"Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: Current data and future prospects. BMC Med. 2015;13:e188.","journal-title":"BMC Med"},{"issue":"21","key":"1856_CR26","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SYN, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588\u201399.","journal-title":"Cancer Res"},{"key":"1856_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1101\/gad.334516.119","volume":"34","author":"D Slade","year":"2020","unstructured":"Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020;34:360\u201394.","journal-title":"Genes Dev"},{"issue":"26","key":"1856_CR28","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"9","key":"1856_CR29","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384.","journal-title":"Lancet Oncol"},{"issue":"22","key":"1856_CR30","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"25","key":"1856_CR31","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"98","key":"1856_CR32","doi-asserted-by":"publisher","first-page":"37080","DOI":"10.18632\/oncotarget.26354","volume":"9","author":"K Sun","year":"2018","unstructured":"Sun K, Mikule K, Wang Z, et al. A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget. 2018;9(98):37080\u201396.","journal-title":"Oncotarget"},{"key":"1856_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/diagnostics9020055","volume":"9","author":"S Boussios","year":"2019","unstructured":"Boussios S, Karathanasi A, Cooke D, et al. PARP inhibitors in ovarian cancer: The route to Ithaca. Diagnostics. 2019;9:55.","journal-title":"Diagnostics"},{"issue":"9","key":"1856_CR34","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","volume":"14","author":"SK Sandhu","year":"2013","unstructured":"Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882\u201392.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1856_CR35","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/17425255.2018.1461838","volume":"14","author":"TC Longoria","year":"2018","unstructured":"Longoria TC, Tewari KS. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer. Expert Opin Drug Metab Toxicol. 2018;14(5):543\u201350.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1856_CR36","unstructured":"Zejula, Niraparib Food and Drug Administration. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208447s015s017lbledt.pdf"},{"key":"1856_CR37","unstructured":"LYNPARZA, Olaparib Food and Drug Administration. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208558s000lbl.pdf"},{"issue":"1","key":"1856_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00280-017-3455-x","volume":"81","author":"L Van Andel","year":"2018","unstructured":"Van Andel L, Rosing H, Zhang Z, et al. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14\u00a0C-microtracer and therapeutic dose in cancer patients. Cancer Chemother Pharmacol. 2018;81(1):39\u201346.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"14","key":"1856_CR39","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1080\/14656566.2021.1952181","volume":"22","author":"EA Hobbs","year":"2021","unstructured":"Hobbs EA, Litton JK, Yap TA. Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer. Expert Opin Pharmacother. 2021;22(14):1825\u201337.","journal-title":"Expert Opin Pharmacother"},{"key":"1856_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ph16091261","volume":"16","author":"MFP Maiorano","year":"2023","unstructured":"Maiorano MFP, Maiorano BA, Biancofiore A, et al. Niraparib and advanced ovarian cancer: a beacon in the non-BRCA mutated setting. Pharmaceuticals. 2023;16:e1261.","journal-title":"Pharmaceuticals"},{"key":"1856_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.crchbi.2022.100027","volume":"2","author":"DS Bejan","year":"2022","unstructured":"Bejan DS, Cohen MS. Methods for profiling the target and off-target landscape of PARP inhibitors. Curr Res Chem Bio. 2022;2:100027.","journal-title":"Curr Res Chem Bio"},{"issue":"6","key":"1856_CR42","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10637-017-0451-2","volume":"35","author":"L Van Andel","year":"2017","unstructured":"Van Andel L, Zhang Z, Lu S, et al. Human mass balance study and metabolite profiling of 14\u00a0C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Invest New Drugs. 2017;35(6):751\u201365.","journal-title":"Invest New Drugs"},{"issue":"5","key":"1856_CR43","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00280-021-04329-8","volume":"88","author":"M Akce","year":"2021","unstructured":"Akce M, El-Khoueiry A, Piha-Paul SA, et al. Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment. Cancer Chemother Pharmacol. 2021;88(5):825\u201336.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1856_CR44","doi-asserted-by":"publisher","first-page":"e967633","DOI":"10.3389\/fphar.2022.967633","volume":"13","author":"N Wang","year":"2022","unstructured":"Wang N, Yang Y, Jin D, et al. PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies. Front Pharmacol. 2022;13:e967633.","journal-title":"Front Pharmacol"},{"key":"1856_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.18632\/oncoscience.610","volume":"11","author":"Y Huang","year":"2024","unstructured":"Huang Y, Chen S, Yao N, et al. Molecular mechanism of PARP inhibitor resistance. Oncoscience. 2024;11:69\u201391.","journal-title":"Oncoscience"},{"key":"1856_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bcp.2018.10.011","volume":"167","author":"A Mukhopadhyay","year":"2019","unstructured":"Mukhopadhyay A, Drew Y, Matheson E, et al. Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors. Biochem Pharmacol. 2019;167:125\u201332.","journal-title":"Biochem Pharmacol"},{"key":"1856_CR47","unstructured":"Clinical trials. https:\/\/clinicaltrials.gov\/"},{"issue":"8","key":"1856_CR48","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","volume":"5","author":"S Vinayak","year":"2019","unstructured":"Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5(8):1132\u201340.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1856_CR49","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.ijrobp.2022.07.412","volume":"114","author":"JC Keenan","year":"2022","unstructured":"Keenan JC, Dunn SA, Collins ME, et al. A Phase I study of adjuvant niraparib administered concurrently with postoperative radiation therapy in patients with localized triple negative breast cancer. Int J Rad Oncol. 2022;114(3):S44.","journal-title":"Int J Rad Oncol"},{"key":"1856_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38534-6","volume":"9","author":"Z Wang","year":"2019","unstructured":"Wang Z, Sun K, Xiao Y, et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep. 2019;9:1853.","journal-title":"Sci Rep"},{"issue":"13","key":"1856_CR51","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.18632\/oncotarget.2083","volume":"5","author":"KA Bridges","year":"2014","unstructured":"Bridges KA, Toniatti C, Buser CA, et al. Niraparib (MK-4827), a novel poly (ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 2014;5(13):5076\u201386.","journal-title":"Oncotarget"},{"issue":"6","key":"1856_CR52","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","volume":"129","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati D, Haro-Silerio JI, Yap TA, et al. PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. 2023;129(6):904\u201316.","journal-title":"Br J Cancer"},{"issue":"9","key":"1856_CR53","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1080\/15384047.2018.1472189","volume":"19","author":"L Booth","year":"2018","unstructured":"Booth L, Roberts J, Poklepovic A, et al. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells. Cancer Biol Ther. 2018;19(9):786\u201396.","journal-title":"Cancer Biol Ther"},{"issue":"12","key":"1856_CR54","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1136\/ijgc-2023-004944","volume":"33","author":"F Heitz","year":"2023","unstructured":"Heitz F, Marth C, Henry S, et al. AGO-OVAR 28\/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial. Int J Gynecol Cancer. 2023;33(12):1966\u20139.","journal-title":"Int J Gynecol Cancer"},{"key":"1856_CR55","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ygyno.2023.10.005","volume":"178","author":"LM Randall","year":"2023","unstructured":"Randall LM, O\u2019Malley DM, Monk BJ, et al. Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE\/GOG-3032). Gynecol Oncol. 2023;178:161\u20139.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"1856_CR56","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1093\/oncolo\/oyad008","volume":"28","author":"KN Chi","year":"2023","unstructured":"Chi KN, Fleshner N, Chiuri VE, et al. Niraparib with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer: Phase II QUEST study results. Oncologist. 2023;28(5):e309\u2013312.","journal-title":"Oncologist"},{"issue":"2","key":"1856_CR57","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ygyno.2022.05.020","volume":"166","author":"MM Hardesty","year":"2022","unstructured":"Hardesty MM, Krivak TC, Wright GS, et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol. 2022;166(2):219\u201329.","journal-title":"Gynecol Oncol"},{"issue":"18","key":"1856_CR58","doi-asserted-by":"publisher","first-page":"18654","DOI":"10.1002\/cam4.6475","volume":"12","author":"D Starks","year":"2023","unstructured":"Starks D, Rojas-Espaillat L, Meissner T, et al. A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers. Cancer Med. 2023;12(18):18654\u201365.","journal-title":"Cancer Med"},{"issue":"4","key":"1856_CR59","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","volume":"32","author":"XH Wu","year":"2021","unstructured":"Wu XH, Zhu JQ, Yin RT, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2021;32(4):512\u201321.","journal-title":"Ann Oncol"},{"issue":"7","key":"1856_CR60","first-page":"758","volume":"29","author":"MR Smith","year":"2023","unstructured":"Smith MR, Sandhu S, George DJ, et al. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects. J Manag Care Spec Pharm. 2023;29(7):758\u201368.","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"1856_CR61","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk BJ, Barretina-Ginesta MP, Pothuri B, et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann Oncol. 2024;35(11):981\u201392.","journal-title":"Ann Oncol"},{"issue":"8","key":"1856_CR62","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","volume":"5","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-Arm Phases 1 and 2 Trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5(8):1141\u20139.","journal-title":"JAMA Oncol"},{"issue":"5","key":"1856_CR63","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):636\u201348.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1856_CR64","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1470-2045(19)30515-7","volume":"20","author":"MR Mirza","year":"2019","unstructured":"Mirza MR, \u00c5vall Lundqvist E, Birrer MJ, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2\/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019;20(10):1409\u201319.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1856_CR65","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","volume":"159","author":"MR Mirza","year":"2020","unstructured":"Mirza MR, Benigno B, D\u00f8rum A, et al. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16\/NOVA trial. Gynecol Oncol. 2020;159(2):442\u20138.","journal-title":"Gynecol Oncol"},{"key":"1856_CR66","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.18.02238","volume":"37","author":"JM Del Campo","year":"2019","unstructured":"Del Campo JM, Matulonis UA, Malander S, et al. niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial. J Clin Oncol. 2019;37:2968\u201373.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1856_CR67","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s40265-017-0752-y","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ. Niraparib: first global approval. Drugs. 2017;77(9):1029\u201334.","journal-title":"Drugs"},{"key":"1856_CR68","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s40265-021-01539-5","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Dostarlimab: first approval. Drugs. 2021;81:1213\u20139.","journal-title":"Drugs"},{"key":"1856_CR69","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/curroncol29010029","volume":"29","author":"A Pagkali","year":"2022","unstructured":"Pagkali A, Mamais I, Michalinos A, et al. Safety profile of niraparib as maintenance therapy for ovarian cancer: A systematic review and meta-analysis. Curr Oncol. 2022;29:321\u201336.","journal-title":"Curr Oncol"},{"key":"1856_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100744","volume":"55","author":"M Chiappa","year":"2021","unstructured":"Chiappa M, Guffanti F, Bertoni F, et al. Overcoming PARPi resistance: preclinical and clinical evidence in ovarian cancer. Drug Resist Updat. 2021;55:100744.","journal-title":"Drug Resist Updat"},{"key":"1856_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02355-1","volume":"24","author":"Y Zou","year":"2025","unstructured":"Zou Y, Zhang H, Chen P, et al. Clinical approaches to overcome PARP inhibitor resistance. Mol Cancer. 2025;24:156.","journal-title":"Mol Cancer"},{"issue":"6691","key":"1856_CR72","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1126\/science.adl5364","volume":"384","author":"L Lu","year":"2024","unstructured":"Lu L, Gou X, Tan SK, et al. De novo design of drug-binding proteins with predictable binding energy and specificity. Science. 2024;384(6691):106\u201312.","journal-title":"Science"},{"key":"1856_CR73","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s43018-024-00857-3","volume":"5","author":"M Senior","year":"2024","unstructured":"Senior M. Beyond the hype of AI in cancer R&d. Nat Cancer. 2024;5:1759\u201361.","journal-title":"Nat Cancer"},{"key":"1856_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-022-00870-7","volume":"29","author":"YY Chu","year":"2022","unstructured":"Chu YY, Yam C, Yamaguchi H, et al. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors. J Biomed Sci. 2022;29:86.","journal-title":"J Biomed Sci"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01856-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01856-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01856-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:07:50Z","timestamp":1777388870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01856-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1856"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01856-1","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to amend the italic text to roman throughout the article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}